FAST (2015–2019) was directly focused on functionally graded scaffolds produced by hybrid additive manufacturing, the project for which Polyvation received EUR 249,625 as a participant.
POLYVATION BV
Dutch polymer SME producing functionally graded additive manufacturing scaffolds for biomedical and advanced manufacturing applications.
Their core work
Polyvation BV is a Groningen-based polymer technology SME that designs and fabricates advanced functional polymer structures, with a focus on additive manufacturing of scaffolds with spatially varying material properties. Their work on functionally graded scaffolds — structures where composition or mechanical properties change across the volume — places them at the intersection of materials science and precision manufacturing. They contribute industrial and technical expertise to academic-led consortia, including serving as an industry host in Marie Curie training networks. The company's name ("Poly" + "vation") and project footprint together suggest a core identity built around polymer innovation for biomedical and advanced manufacturing applications.
What they specialise in
FAST's full title — 'Functionally graded Additive Manufacturing scaffolds by hybrid manufacturing' — makes this the defining technical specialty of their funded H2020 work.
NANOMED (2016–2019) was an MSCA-ITN training network on nanomedicine, where Polyvation participated as an industrial third party — likely hosting fellows or providing applied polymer expertise.
Both FAST (scaffolds for tissue engineering contexts) and NANOMED (drug delivery and nanoparticle systems) point toward a biomedical application thread, though neither project makes the clinical context explicit.
How they've shifted over time
With only two projects, both launched within a year of each other (2015 and 2016) and running concurrently through 2019, there is no meaningful early-to-late trajectory to analyze — this is a single cohort of activity rather than a progression. No keyword data is available from CORDIS to differentiate their focus within that period. What can be said is that Polyvation entered H2020 simultaneously on two fronts: a manufacturing RIA focused on scaffold fabrication, and an MSCA training network in nanomedicine, suggesting from the outset a deliberate positioning across both applied manufacturing and life-science research communities.
Their dual entry into manufacturing and nanomedicine simultaneously suggests Polyvation is building toward biomedical polymer applications — a logical trajectory for a polymer SME seeking to move up the value chain from fabrication into healthcare-adjacent markets.
How they like to work
Polyvation has never served as a project coordinator — they enter consortia as a participant or third party, contributing specialist capability rather than driving the project agenda. Despite only two projects, they accumulated 20 unique consortium partners across 10 countries, which reflects participation in large, well-networked consortia rather than small bilateral arrangements. This pattern is typical of an SME that is recruited for its specific technical niche and that gains broad European exposure without taking on administrative leadership risk.
Polyvation has reached 20 unique partners across 10 countries through just two projects, reflecting the large consortia typical of RIA and MSCA-ITN schemes. Their network is European in scope with no documented focus on any particular geographic cluster beyond the Netherlands.
What sets them apart
Polyvation occupies a rare niche as a small polymer manufacturer with simultaneous credibility in precision fabrication (functionally graded additive manufacturing) and biomedical research networks (MSCA nanomedicine). For consortium builders, this means they bring both hands-on production capability and the legitimacy of having worked within academic-led life science projects — a combination that pure research institutes and pure manufacturers cannot offer alone. Located in Groningen, they sit close to the University of Groningen's strong polymer and biomedical research ecosystem, which likely underpins their access to these consortia.
Highlights from their portfolio
- FASTTheir sole directly funded H2020 project (EUR 249,625), addressing a technically specific challenge — producing scaffolds with graded material properties via hybrid additive manufacturing — that sits at the frontier of both manufacturing process engineering and biomedical material design.
- NANOMEDParticipation as an industrial third party in a Marie Curie training network signals that Polyvation is recognized as a credible industry host for early-career researchers in nanomedicine, a role that builds long-term academic-industry network value beyond direct project funding.